Biostate AI, a scalable biodata foundry startup based in Palo Alto, CA, has raised $4 million in funding. The round was led by Matter Venture Partners, with participation from Vision Plus Capital, Catapult VC, the Caltech Seed Fund, Dario Amodei, Joris Poort, Michael Schnall-Levin , and Emily Leproust.
Founded in 2023 and led by CEO David Zhang, Biostate AI aims to develop generative AI to benefit human health. The company’s Total RNA sequencing employs patent-pending Barcode-Integrated Reverse Transcription (BIRT) technology to analyze various types of RNA, including long non-coding RNAs (lncRNAs), micro RNAs (miRNAs), circular RNAs (circRNAs), and enhancer RNAs (eRNAs).
Biostate AI recently launched OmicsWeb Copilot, a conversational AI designed to help biologists analyze and visualize data. Copilot uses large-language models (LLMs) to understand user requests and generate customized software and scripts for data analysis. It also provides access to over 1,000 unique RNAseq datasets collected by the Biostate team, in addition to analyzing users’ own uploaded data.
With offices and laboratories in Palo Alto, CA, and Houston, TX, Biostate AI collaborates with academic, nonprofit, and industry partners on technology development and multiomic biodata collection.
CEO David Zhang commented, “Biostate AI has developed instrumental technologies to facilitate the collection of more biological data at lower costs. We are pleased to offer these capabilities to academic and industry partners and collaborators.”
The newly raised funds will be used to expand Biostate AI’s operations and development efforts.
